Earnings Snapshot: Teva Pharmaceutical Industries tops Q1 estimates; maintains 2026 business outlook [Seeking Alpha]
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year [Yahoo! Finance]
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy [Yahoo! Finance]